News | August 16, 2021
IOL Chemicals and Pharma commissions Unit-10 for Rs 28.69 crores
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
Investment of Rs 235 crores to add 411 beds in the next 18 months
The group has a total of 320 ANDA approvals
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Substantial reduction in losses
Demand normalisation post the second wave contributed to the steady growth
The company is eligible for 12 months exclusivity from launch
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
The aim is to create new genomics solutions that could combat cancer and advance market access
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Subscribe To Our Newsletter & Stay Updated
